Innovent Biologics Beheer

Beheer criteriumcontroles 2/4

De CEO Innovent Biologics is Michael Yu, benoemd in Jan2011, heeft een ambtstermijn van 14.33 jaar. De totale jaarlijkse vergoeding van { bedraagt CN¥ 40.60M, bestaande uit 7.1% salaris en 92.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 6.51% van de aandelen van het bedrijf, ter waarde € 672.49M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.2 jaar en 3.8 jaar.

Belangrijke informatie

Michael Yu

Algemeen directeur

CN¥40.6m

Totale compensatie

Percentage CEO-salaris	7.14%
Dienstverband CEO	14.3yrs
Eigendom CEO	6.5%
Management gemiddelde ambtstermijn	1.2yrs
Gemiddelde ambtstermijn bestuur	3.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Michael Yu's beloning veranderd ten opzichte van Innovent Biologics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Dec 31 2024	CN¥41m	CN¥3m	-CN¥95m
Sep 30 2024	n/a	n/a	-CN¥688m
Jun 30 2024	n/a	n/a	-CN¥1b
Mar 31 2024	n/a	n/a	-CN¥1b
Dec 31 2023	CN¥36m	CN¥3m	-CN¥1b
Sep 30 2023	n/a	n/a	-CN¥1b
Jun 30 2023	n/a	n/a	-CN¥1b
Mar 31 2023	n/a	n/a	-CN¥2b
Dec 31 2022	CN¥33m	CN¥3m	-CN¥2b
Sep 30 2022	n/a	n/a	-CN¥2b
Jun 30 2022	n/a	n/a	-CN¥3b
Mar 31 2022	n/a	n/a	-CN¥3b
Dec 31 2021	CN¥26m	CN¥3m	-CN¥3b
Sep 30 2021	n/a	n/a	-CN¥2b
Jun 30 2021	n/a	n/a	-CN¥1b
Mar 31 2021	n/a	n/a	-CN¥1b
Dec 31 2020	CN¥105m	CN¥3m	-CN¥998m
Sep 30 2020	n/a	n/a	-CN¥1b
Jun 30 2020	n/a	n/a	-CN¥2b
Mar 31 2020	n/a	n/a	-CN¥2b
Dec 31 2019	CN¥76m	CN¥3m	-CN¥2b

Compensatie versus markt: De totale vergoeding ($USD 5.62M ) Michael } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 5.24M ).

Compensatie versus inkomsten: De vergoeding van Michael is gestegen terwijl het bedrijf verliesgevend is.

CEO

Michael Yu (60 yo)

14.3yrs

Tenure

CN¥40,599,000

Compensatie

Dr. De-Chao Yu, also known as Michael, Ph.D. Co-Founded Innovent Biologics, Inc. in August 2011 and has been its Chairman and Chief Executive Officer since 2011. He served as its President at Innovent Biol...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
De-Chao Yu	Co-Founder	14.3yrs	CN¥40.60m	6.51% € 672.5m
Qian Zhang	Chief People Officer	5.8yrs	CN¥2.79m	0.020% € 2.1m
Hao Xi Ede	Executive Director & Fund Managing Partner	1.3yrs	CN¥7.15m	0.20% € 20.4m
Fei You	Chief Financial Officer	1.3yrs	geen gegevens	geen gegevens
Cong Ding	General Counsel	less than a year	geen gegevens	geen gegevens
Min Liu	Chief Commercial Officer	no data	geen gegevens	geen gegevens
Blake Salisbury	Senior Vice President	no data	geen gegevens	geen gegevens
Hui Zhou	Senior Vice President	1.3yrs	geen gegevens	geen gegevens
Samuel Suhua Zhang	Global Chief Business Officer	1.1yrs	geen gegevens	geen gegevens
Raj Dhodda	Senior Vice President	1yr	geen gegevens	geen gegevens
Lei Qian	Senior Vice President	less than a year	geen gegevens	geen gegevens
Kaisong Zhou	Senior Vice President	less than a year	geen gegevens	geen gegevens

1.2yrs

Gemiddelde duur

53.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 6IB wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.2 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
De-Chao Yu	Co-Founder	14.3yrs	CN¥40.60m	6.51% € 672.5m
Qian Zhang	Chief People Officer	1yr	CN¥2.79m	0.020% € 2.1m
Hao Xi Ede	Executive Director & Fund Managing Partner	no data	CN¥7.15m	0.20% € 20.4m
Charles Leland Cooney	Member of CMC Strategic Advisory Board & Independent Non-Executive Director	9.6yrs	CN¥400.00k	0.0027% € 284.1k
Lewis L. Lanier	Member of Scientific Advisory Board	3.8yrs	geen gegevens	geen gegevens
I-Yin Hsu	Independent Non-Executive Director	6.6yrs	CN¥400.00k	0.00038% € 39.3k
Erwin Vanhaecke	Member of CMC Strategic Advisory Board	no data	geen gegevens	geen gegevens
Chiang Syin	Member of CMC Strategic Advisory Board	no data	geen gegevens	geen gegevens
David LaPre	Member of CMC Strategic Advisory Board	no data	geen gegevens	geen gegevens
Shuyun Chen	Lead Independent Non-Executive Director	1yr	CN¥267.00k	0.00067% € 69.2k
Lawrence Fong	Member of Scientific Advisory Board	3.8yrs	geen gegevens	geen gegevens
Carlos Garcia-Echeverria	Member of Scientific Advisory Board	3.8yrs	geen gegevens	geen gegevens

3.8yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 6IB wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2025/05/20 22:39
Aandelenkoers aan het einde van de dag	2025/05/20 00:00
Inkomsten	2024/12/31
Jaarlijkse inkomsten	2024/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Innovent Biologics, Inc. wordt gevolgd door 57 analisten. 29 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Bo Li	BofA Global Research
Shun Kei Law	CCB International Securities Limited
Zhishun Siu	CCB International Securities Limited

Innovent Biologics Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Innovent Biologics, Inc. Announces Board and Committee Appointments

Innovent Biologics, Inc., Annual General Meeting, Jun 25, 2025

Co-Founder recently sold €9.5m worth of stock

Innovent Biologics, Inc. Announces Change in Composition of Board Committees

High number of new directors

Innovent Biologics, Inc. Appoints Samuel Zhang as Global Chief Business Officer

Recent updates

Innovent Biologics, Inc. Announces Second Head-To-head Phase 3 Study of Mazdutide versus Semaglutide Completes First Participant Dosing in Adults in China with Overweight or Obesity Accompanied Fatty Liver Disease (GLORY-3)

Innovent Biologics, Inc. Announces Oral Presentation of Full Phase 2 Clinical Data for Efdamrofusp Alfa (IBI302)

Innovent Announces First Patient Dosed in the Phase 2 Clinical Study of Efdamrofusp Alfa

Innovent Biologics, Inc. Announces First Patient Dosed in Phase 1 Study of IBI3020, Global First-In-Class Dual Payload CEACAM5 ADC, in Patients with Advanced Malignancies

Innovent Biologics, Inc. Announces NMPA Approval of Limertinib, a Third-Generation EGFR TKI Collaborated with ASK Pharma, for the First-Line Treatment of Lung Cancer

Innovent Biologics, Inc. Announces Board and Committee Appointments

Innovent Biologics, Inc., Annual General Meeting, Jun 25, 2025

Hutchmed (China) Limited and Innovent Biologics, Inc. Jointly Announce the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab

Innovent Biologics, Inc. Announces China's First IGF-1R Monoclonal Antibody Sycume® Received Approval by the National Medical Products Administration for the Treatment of Thyroid Eye Disease

Innovent Biologics, Inc. to Report Fiscal Year 2024 Results on Mar 26, 2025

Innovent Biologics, Inc. Announces the New Drug Application of Ipilimumab Injection

Innovent Biologics, Inc. and Jiangsu Aosaikang Pharmaceutical Co. Ltd. Jointly Announce NMPA Approval of Limertinib, a Third-Generation EGFR TKI for the Treatment of Lung Cancer

Innovent Biologics, Inc. Announces National Medical Products Administration of China Approves Second New Drug Application of DOVBLERON

Innovent Biologics, Inc. announced that it has received funding from Xuhui Science and Technology Venture Capital

Innovent Biologics, Inc. Receives Approval of DOVBLERON®? (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

Innovent Presents Updated Data from Innovative Anti-CLDN18.2 Adc (Ibi343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the Esmo Asia Congress 2024

Innovent Biologics, Inc. Announces First-Time Inclusion of SINTBILO and New Indication for Olverembatinib in China's National Reimbursement Drug List

New major risk - Share price stability

Forecast to breakeven in 2025

Co-Founder recently sold €9.5m worth of stock

First half 2024 earnings released: CN¥0.24 loss per share (vs CN¥0.091 loss in 1H 2023)

Innovent Biologics, Inc. Announces Acceptance of New Drug Application for Picankibart Injection by China's NMPA

Innovent Biologics, Inc. Announces Clinical Data of IBI363 (First-in-class PD-1/IL-2a-bias Bispecific Antibody Fusion Protein) Combined with Bevacizumab in Advanced Colorectal Cancer at the 2024 ESMO Congress

Forecast to breakeven in 2025

Innovent Biologics, Inc. Announces Change in Composition of Board Committees

First half 2024 earnings released: CN¥0.24 loss per share (vs CN¥0.091 loss in 1H 2023)

Innovent Biologics, Inc. Announces the Approval of Dupert® (Fulzerasib) by the National Medical Products Administration of China

The National Medical Products Administration Approves Centre for Drug Evaluation of the National Medical Products Administration of China's First KRAS G12C Inhibitor Dupert

Innovent Biologics, Inc. to Report First Half, 2024 Results on Aug 28, 2024

Innovent Biologics, Inc. and Sanegene Bio USA Inc. Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3016 (AGT siRNA)

the National Medical Products Administration of China Accepts the New Drug Application of Mazdutide of Innovent Biologics, Inc

Forecast to breakeven in 2025

Innovent Biologics, Inc. Presents the Results of the First Phase 3 Study of Mazdutide for Weight Management at the ADA's 84th Scientific Sessions

High number of new directors

Innovent Biologics, Inc. Announces Picankibart (IBI112) Achieved Primary Endpoints in A Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to the NDA to the NMPA

Innovent Biologics Announces National Medical Products Administration of China Accepts the New Drug Application for IBI311

Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer

Full year 2023 earnings released: CN¥0.66 loss per share (vs CN¥1.46 loss in FY 2022)

Innovent Biologics, Inc. Appoints Samuel Zhang as Global Chief Business Officer

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

Innovent Biologics, Inc. Announces the National Medical Products Administration Accepts the New Drug Application

Innovent Biologics, Inc., Annual General Meeting, Jun 21, 2024

Full year 2023 earnings released

Innovent Biologics, Inc. Releases the Results of Two Clinical Studies of Ibi311 (An Anti-IGF-1R Monoclonal Antibody) in Oral Presentations At the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024

Anheart Therapeutics and Innovent Announces China’s NMPA Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of Ros1-Positive Lung Cancer

Innovent Biologics, Inc. to Report Fiscal Year 2023 Results on Mar 20, 2024

Innovent Biologics, Inc. Announces the Phase 3 Clinical Study of Ibi311 Met the Primary Endpoint in Treating Thyroid Eye Disease

Innovent Biologics, Inc. Announces Appointment of Shun Lu as Independent Non-Executive Director and A Member of the Strategy Committee

Innovent Biologics, Inc.'s First New Drug Application of Mazdutide for Chronic Weight Management Has Been Accepted by the NMPA of China

Innovent Biologics, Inc. Announces Chief Financial Officer Changes

Innovent Biologics, Inc. Announces the First Phase 3 Clinical Trial of Mazdutide Inchinese Adults with Overweight or Obesity Metthe Primary and All Key Secondary Endpoints

China’S National Medical Products Administration Grants Anheart Therapeutics and Innovent Biologics, Inc. Taletrectinib (Ros1 Inhibitor) Priority Review Designation for the New Drug Application (Nda) of Taletrectinib

Innovent Biologics, Inc. Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications

Innovent Biologics, Inc. Announces the Phase 3 Orient-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Forecast to breakeven in 2025

Innovent Biologics, Inc. Announces the National Medical Products Administration of China Accepts and Grants Priority Review Designation to the New Drug Application for IBI351

Innovent Biologics, Inc. Announces Acceptance of New Drug Application from National Medical Products Administration for Taletrectinib

Innovent Biologics, Inc Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Type 2 Diabetes in Diabetes Care

The National Medical Products Administration Approves Olverembatinib for the Treatment of Cml-Cp Patients

Innovent Biologics, Inc. Announces Robust Weight Loss Efficacy, Multiple Metabolic Benefits and Favorable Safety Profile of Higher Dose 9 mg Mazdutide (IBI362) after 48-week Treatment in Phase 2 Study for Obesity

Innovent Biologics, Inc. Announces Update on the New Drug Application for Parsaclisib (PI3Kd Inhibitor)

Now 20% undervalued

Innovent Biologics, Inc. has completed a Follow-on Equity Offering in the amount of HKD 2.35688 billion.

New minor risk - Shareholder dilution

First half 2023 earnings released: CN¥0.091 loss per share (vs CN¥0.65 loss in 1H 2022)

National Medical Products Administration Approves New Drug Application for Innovent Biologics, Inc.'s Sintbilo

New major risk - Share price stability

Innovent Biologics, Inc. to Report Q2, 2023 Results on Aug 23, 2023

IASO Bio and Innovent Announce the NMPA Approval of the New Drug Application for Equecabtagene Autoleucel, the World's First Fully-human BCMA CAR-T Therapy, for the Treatment of Relapsed and/or Refractory Multiple Myeloma